CA2772708C - Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles - Google Patents

Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles Download PDF

Info

Publication number
CA2772708C
CA2772708C CA2772708A CA2772708A CA2772708C CA 2772708 C CA2772708 C CA 2772708C CA 2772708 A CA2772708 A CA 2772708A CA 2772708 A CA2772708 A CA 2772708A CA 2772708 C CA2772708 C CA 2772708C
Authority
CA
Canada
Prior art keywords
dosage form
magnetic field
phases
magnetized
magnetizable particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2772708A
Other languages
English (en)
French (fr)
Other versions
CA2772708A1 (en
Inventor
Benedikt Hartwig
Norbert Windhab
Melanie Liefke
Juan Tome Alcalde
Michael Damm
Rosario Lizio
Michael Gottschalk
Angela Olf
Christian Meier
Andreas Gryczke
Original Assignee
Roehm GmbH Darmstadt
Evonik Operations GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roehm GmbH Darmstadt, Evonik Operations GmbH filed Critical Roehm GmbH Darmstadt
Publication of CA2772708A1 publication Critical patent/CA2772708A1/en
Application granted granted Critical
Publication of CA2772708C publication Critical patent/CA2772708C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2772708A 2009-09-03 2010-08-30 Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles Active CA2772708C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23961309P 2009-09-03 2009-09-03
US61/239,613 2009-09-03
DE102009029170.9 2009-09-03
DE102009029170 2009-09-03
PCT/EP2010/062641 WO2011026808A1 (en) 2009-09-03 2010-08-30 Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles

Publications (2)

Publication Number Publication Date
CA2772708A1 CA2772708A1 (en) 2011-03-10
CA2772708C true CA2772708C (en) 2017-07-11

Family

ID=42984007

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2772708A Active CA2772708C (en) 2009-09-03 2010-08-30 Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles

Country Status (13)

Country Link
US (1) US9050256B2 (https=)
EP (1) EP2473095B1 (https=)
JP (1) JP5868319B2 (https=)
KR (1) KR101731130B1 (https=)
CN (1) CN102573612B (https=)
BR (1) BR112012004967B8 (https=)
CA (1) CA2772708C (https=)
ES (1) ES2528494T3 (https=)
IL (1) IL217897A (https=)
MX (1) MX2012002677A (https=)
PL (1) PL2473095T3 (https=)
SI (1) SI2473095T1 (https=)
WO (1) WO2011026808A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140341983A1 (en) * 2011-09-14 2014-11-20 Donn M. Dennis Smart™ solid oral dosage forms
DE102011089334A1 (de) * 2011-12-21 2013-06-27 Evonik Röhm Gmbh Detektionssystem zur Erfassung magnetischer Objekte im menschlichen Organismus
US11667906B2 (en) * 2014-11-24 2023-06-06 Corning Incorporated Magnetic microcarriers
US11024449B2 (en) * 2017-06-06 2021-06-01 Apple Inc. Multipole elastomeric magnet with magnetic-field shunt
CA3084087A1 (en) 2017-12-04 2019-06-13 Evonik Operations Gmbh Masking and subsequently visualising esr signals using the combination of two materials
US10824822B2 (en) * 2019-02-05 2020-11-03 International Business Machines Corporation Magnetic tracking for medicine management
US10679018B1 (en) 2019-02-05 2020-06-09 International Business Machines Corporation Magnetic tracking for medicine management
JP7502741B2 (ja) * 2019-09-26 2024-06-19 スピンセンシングファクトリー株式会社 磁気マーカーおよび磁気マーカー検出システム
AU2021356684A1 (en) 2020-10-09 2023-05-11 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
CN112360304A (zh) * 2020-11-06 2021-02-12 炫丽建材江苏有限公司 一种适用于22度免拉手门板的自愈合封边工艺
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
WO2022216977A1 (en) 2021-04-07 2022-10-13 Batelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
JP2025512969A (ja) 2022-04-06 2025-04-22 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ｈｅｒ２陽性転移性乳がん及び他のがんを治療するための組成物及び方法
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3723310A1 (de) * 1987-07-15 1989-01-26 John Urquhart Pharmazeutisches praeparat und verfahren zu seiner herstellung
DE3740187A1 (de) 1987-11-27 1989-06-08 Urquhart John Verfahren und vorrichtung zum ueberwachen und/oder kontrollieren und/oder registrieren und/oder anzeigen der einnahme von pharmazeutischen praeparaten
DE3940260A1 (de) 1989-03-04 1990-09-13 Werner Weitschies Verfahren zur bestimmung des aufenthaltsortes und der bewegung von objekten durch ihre markierung als magnetisches moment
CN1056049C (zh) 1994-02-02 2000-09-06 湖南省商业科技研究所 一种磁疗食品的制备方法
US6081734A (en) 1996-08-16 2000-06-27 Roche Diagnostics Gmbh Monitoring system for the regular intake of a medicament
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
EP1557151A1 (en) 2004-01-22 2005-07-27 F. Hoffmann-La Roche Ag Solid dosage form
CN100355454C (zh) * 2005-10-25 2007-12-19 南京工业大学 磁热疗用纳米磁粉－抗人肝癌单抗HAb18靶向药物
EP1880716A1 (en) 2006-07-19 2008-01-23 Sandoz AG Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
DE102008033662A1 (de) 2008-07-11 2010-01-14 Technische Universität Ilmenau Pharmakologische Darreichungsform und Vorrichtung und Verfahren zur kontinuierlichen Lokalisierung und Verfolgung des Auflösevorganges dieser

Also Published As

Publication number Publication date
JP2013503831A (ja) 2013-02-04
IL217897A0 (en) 2012-03-29
WO2011026808A1 (en) 2011-03-10
ES2528494T3 (es) 2015-02-10
CN102573612B (zh) 2015-07-08
JP5868319B2 (ja) 2016-02-24
EP2473095A1 (en) 2012-07-11
KR20120060210A (ko) 2012-06-11
US9050256B2 (en) 2015-06-09
US20120143039A1 (en) 2012-06-07
HK1168016A1 (en) 2012-12-21
BR112012004967A2 (pt) 2016-04-05
SI2473095T1 (sl) 2015-02-27
IL217897A (en) 2014-06-30
PL2473095T3 (pl) 2015-04-30
KR101731130B1 (ko) 2017-05-11
BR112012004967B1 (pt) 2021-05-11
CA2772708A1 (en) 2011-03-10
EP2473095B1 (en) 2014-11-12
MX2012002677A (es) 2012-04-11
WO2011026808A8 (en) 2012-03-15
BR112012004967B8 (pt) 2022-07-05
CN102573612A (zh) 2012-07-11

Similar Documents

Publication Publication Date Title
CA2772708C (en) Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles
RU2598341C2 (ru) Система детектирования для регистрации магнитных объектов в человеческом организме
Fadda et al. Meal-induced acceleration of tablet transit through the human small intestine
Cole et al. Enteric coated HPMC capsules designed to achieve intestinal targeting
EP1059918A1 (en) Novel dosage form
US12383495B2 (en) Resident articles for gram-level dosing
Goodman et al. Assessing gastrointestinal motility and disintegration profiles of magnetic tablets by a novel magnetic imaging device and gamma scintigraphy
US10165988B2 (en) Personalized detection system for detecting magnetic objects in the human organism
Singh et al. Emerging techniques and challenges in colon drug delivery systems
Chan et al. Comparison of the release profiles of a water soluble drug carried by Eudragit-coated capsules in different in-vitro dissolution liquids
Fassihi et al. Colon-targeted delivery systems for therapeutic applications: drug release from multiparticulate, monolithic matrix, and capsule-filled delivery systems
Marvola et al. Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules for local treatment in colon
CN101125134B (zh) 盐酸坦洛新缓释胶囊及其制备方法
Fassihi Modified-Release delivery systems: extended-release capsule platform
HK1168016B (en) Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles
Brogmann et al. Enteric targeting through enteric coating
Arora et al. Radiopharmaceutical-based approaches for the determination of colon-targeting efficiency
Hodges In Vivo Characterization of Oral Multiparticulate Systems
Lanjhiyana et al. In-vitro and in-vivo release studies of methotrexate from novel enteric coated time-dependent microbial-triggered drug delivery systems for colon specific
Cora et al. Magnetic images with a biosusceptometer of pharmaceutical dosage forms in the human gastrointestinal tract
HK1199397B (en) Detection system for detecting magnetic objects in the human organism
Rezaeifar Multiparticulate systems based on enteric polymers
Shehu et al. Status of Oral Chronopharmaceuticals Drug Delivery System, Latest Technologies, and Hurdles
Cetin et al. In Vitro and In Vivo evaluation of hydroxypropylmethyl cellulose phthalate capsules

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150615

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251210

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251212

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260326

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-6-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260413